Biohaven licensing deal with Ono Pharma for extracellular IgG degraders in Japan
Biohaven (BHVN) signed a licensing agreement with Ono Pharma for extracellular IgG degraders in Japan and select Asian regions, with Biohaven to receive $80M upfront.
Biohaven (BHVN) signed a licensing agreement with Ono Pharma for extracellular IgG degraders in Japan and select Asian regions, with Biohaven to receive $80M upfront.